Ramoplanin – protecting patients against CDAD attacks in hospitals

Ramoplanin – protecting patients against CDAD attacks in hospitals


Ramoplanin is an antibiotic glycolipodepsipeptide drug that can be used as a treatment for patients suffering with Clostridium difficile infection (CDAD infection) of the gastrointestinal tract.

This drug was approved by the US Food and Drug Administration (FDA); however, this drug is considered unstable in the blood, and it degrades to inactive parts. Therefore, Ramoplanin can only be used orally.

Uses of Ramoplanin

A CDAD infection may cause diarrhea, fulminant colitis and may lead to death. Ramoplanin can be used to cure CDAD as it acts as a bactericidal in vitro against C. difficile and other similar bacteria. Efficacy and safety of using this drug was approved through Phase II researches. This drug can be used to manage various pathogens that are commonly found in hospitals; protecting patients against CDAD attacks.

Ongoing researches on Ramoplanin

Duke University conducted medical research concluded that Ramoplanin does interrupt and block production of cell membranes in bacteria. Other recent studies suggest that Ramoplanin can be efficiently used to control and solve problems related to pathogens such as Staphylococcus aureus, Enterococcus faecium, Staphylococcus epidermis and Clostridium difficile. Studies have found that Ramoplanin can be used orally but it cannot be absorbed systemically from gastrointestinal tract and hence it can easily exert its anti-pathogenic activities locally in the GI tract to help patients suffering from CDAD infections such as common diarrhea and serious fulminant colitis and other bacterial diseases.

In 2004, Ramoplanin was a major subject of six medical presentations at the Annual Meeting of the Infectious Diseases Society of America (IDSA). Many scientific researchers are studying the effects of Ramoplanin on patients, and its antimicrobial resistance, biofilms and in vitro activity.

Some of recent studies on Ramoplanin include a Phase III clinical trial of Ramoplanin to cure and prevent bloodstream infections that can be caused by Vancomycin-resistant enterococcus (VRE). Another Phase II study for Ramoplanin is currently underway investigating its efficacy for curing Clostridium difficile-associated diarrhea.

This antibiotic is available for R&D purposes from LGM Pharma. Inquire about Ramoplanin CAS# 76168-82-6 prices, availability, delivery, purity and more.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service